The most common undesirable effects observed with labetalol injection and collected from post-marketing reports include: congestive heart failure, postural hypotension, hypersensitivity, drug fever, raised liver function tests, nasal congestion and erectile dysfunction.
The following convention has been utilised for the classification of frequency: Very common ≥1/10, common ≥1/100, <1/10, uncommon ≥1/1000 and <1/100, rare ≥1/10,000 and <1/1000, very rare <1/10,000, not known (cannot be estimated from the available data).
Side-effects indicated by a hash (#) are usually transient and occur during the first few weeks of treatment.
Tablets: See Table 4.

Description of selected adverse reactions: Immune system disorders: Hypersensitivity reactions reported include rash (including reversible lichenoid rash), pruritus, dyspnoea and very rarely drug fever or angioedema.
Vascular disorders: Postural hypotension is more common at very high doses or if the initial dose is too high or doses are increased too rapidly.
Hepatobiliary disorders: The signs and symptoms of hepatobiliary disorders are usually reversible on withdrawal of the medicinal product.
Injection: See Table 5.

Description of selected adverse reactions: Immune system disorders: Hypersensitivity reactions reported include rash, pruritus, dyspnoea and very rarely, drug fever or angioedema.
Vascular disorders: Pronounced postural hypotension may occur if patients are allowed to assume the upright position within 3 h of receiving labetalol injection.
Hepatobiliary disorders: The signs and symptoms of hepatobiliary disorders are usually reversible on withdrawal of the medicinal product.
View ADR Reporting Link